Dapsone and Autoimmune Bullous Disorders

50.

Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita-successful treatment of colchicine. Arch Dermatol Res. 1994;286(1):35–46.CrossRefPubMed

51.

Cunningham BB, Kirchmann TT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol. 1996;34(5 Pt1):781–4.CrossRefPubMed

52.

Luke MC, Darling TN, Hsu R, et al. Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol. 1999;135(8):954–9.CrossRefPubMed

53.

Yang B, Wang C, Wang N, et al. Childhood epidermolysis bullosa acquisita: report of a Chinese case. Pediatr Dermatol. 2011;29(5):614–7. doi:10.1111/j.1525–1470.2011.01509.x.CrossRefPubMed

54.

Kim JH, Kim YH, Kim SC, et al. Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases. Acta Derm Venereol. 2011;91:307–12.CrossRefPubMed

55.

Zone JJ, Taylor TB, Meyer LJ, Petersen MJ. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol. 1998;110(3):207–10.CrossRefPubMed

56.

Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol. 2012;30(1):38–50.CrossRefPubMed

57.

Egan CA, Zone JJ. Linear IgA bullous dermatosis. Int J Dermatol. 1999;38(11):818–27.CrossRefPubMed

58.

Wojnarowska F. Linear IgA dapsone responsive bullous dermatosis. J R Soc Med. 1980;73(5):371–3.PubMedCentralPubMed

Only gold members can continue reading. Log In or Register to continue